July 27, 2020 – Thermo Fisher Scientific (Carlsbad, CA) is expanding its GlobalAccess Sequencing Program to include laboratories working in oncology.
Originally introduced to accelerate multi-institutional-led studies focused on SARS-CoV-2 (the virus that causes COVID-19), the expanded program now provides support to “labs facing significant constraints as a result of the global pandemic by offering faster access to comprehensive, single-day molecular profiling of tumor tissue on Thermo Fisher’s Ion Torrent Genexus System.”
Through the GlobalAccess Sequencing Program, Thermo Fisher will subsidize a limited number of Genexus Systems for a short time. The program, which is open to pathology laboratories that currently run or wish to begin sequencing samples with oncology assays, is available immediately and will continue through the end of 2020.
“With only five minutes of hands-on time required, the system is designed to minimize user intervention and is conducive for maintaining social distancing requirements in a decentralized lab setting,” the company says.
It also requires minimal amounts of tissue sample and can run small batches cost-effectively.
